It has been shown that GPI–AMFR axis inhibition blocks the development of the metastatic phenotype and the migratory tumor cell capacity.42 In a recent study, we demonstrated that ccRCC cell treated with anti-AMFR antibody, had reduced migratory and invasive capabilities, and a decreased neoangiogenic response.9 Therefore, blocking this axis may serve as a putative therapeutic target for ccRCC. This evidence concerns the gene AMFR and nonpapillary renal cell carcinoma.